Clinical trial
A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT06154447 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 12, 2023
- Completion date
- July 10, 2026
- Enrollment
- 165 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.